SRTS - センサス・ヘルスケア （Sensus Healthcare Inc.）

Sensus Healthcare Inc. (NASDAQ:SRTS) marked $6.40 per share on Wednesday, down from a previous closing price of $6.53. While Sensus Healthcare Inc. has underperformed by -1.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRTS rose by 8.66%, with highs and lows ranging from $15.25 to […]

As of Thursday, Sensus Healthcare Inc.’s (NASDAQ:SRTS) stock closed at $6.67, down from $7.27 the previous day. While Sensus Healthcare Inc. has underperformed by -8.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRTS rose by 20.61%, with highs and lows ranging from $15.25 to $5.26, […]

In the current trading session, Sensus Healthcare Inc.’s (SRTS) stock is trading at the price of $6.72, a gain of 5.91% over last night’s close. So, the stock is trading at a price that is -55.97% less than its 52-week high of $15.25 and 67.88% better than its 52-week low of $4.00. Based on the […]

Sensus Healthcare, Inc. (NASDAQ:NASDAQ:SRTS) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Kim Golodetz - Investor Relations Joe Sardano - Chairman and…

Sensus Healthcare Inc.''s share price started a 2-year period of trading flat before taking off in November 2021. See why SRTS stock is a Hold for now.

BOCA RATON, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS ), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A pre-recorded presentation will be available on demand beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties can access the presentation on the investor relations section of the … Full story available on Benzinga.com

Sensus Healthcare, Inc. (NASDAQ:SRTS) EVP Stephen Brad Cohen sold 14,889 shares of the companys stock in a transaction that occurred on Tuesday, December 14th. The stock was sold at an average price of $7.22, for a total value of $107,498.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which []

Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano sold 13,969 shares of the businesss stock in a transaction that occurred on Tuesday, December 14th. The stock was sold at an average price of $7.22, for a total transaction of $100,856.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which []

Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano sold 13,969 shares of the companys stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $7.22, for a total value of $100,856.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible []

Sensus Healthcare, Inc. (NASDAQ:SRTS) EVP Stephen Brad Cohen sold 22,633 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $7.81, for a total value of $176,763.73. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC []

Sensus Healthcare with ticker code (SRTS) have now 6 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 6 and 2.95 calculating the mean target price we have 4.43. Given that the stocks previous close was at 3.36 this now indicates there is a potential upside of 31.8%. The 50 day MA is 3.13 and the 200 moving average now moves to 2.9. The company has a market capitalisation of $57m. Find out more information at: /> [stock_market_widget type="chart" symbol="SRTS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Sensus Healthcare manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

In a report released today, James Terwilliger from Northland Securities maintained a Buy rating on Sensus Healthcare (SRTS), with a price target of The post Sensus Healthcare (SRTS) Gets a Buy Rating from Northland Securities appeared first on Smarter Analyst .

The proposed Intraoperative Radiation Therapy Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes

Sensus Healthcare Inc. shares closed today 19.6% higher than it did at the end of yesterday. The stock is currently up 18.4% year-to-date, up 12.6% over the past 12 months, and down 21.9% over the past five years. Today, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.5%. Trading Activity Shares traded as high as $6.09 and as low as $3.60 this week.Shares closed 2e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 93.0% lower than the 10-day average and 80.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 11.9% higher than its 5-day moving average, 13.3% higher than its 20-day moving average, and 30.4% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 225.7% The company's stock price performance over the past 12 months lags the peer average by -84.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.